From: The Manchester guidelines for contralateral risk-reducing mastectomy
Family history—<45 years with a first-degree relative (RR 2.5) —<55 years with first degree relative (RR 1.5) —first degree relative with bilateral disease (RR 3.5) Level II evidence (Reiner AS JCO—2013) [18] |
Gene mutation status—BRCA1/2 mutation (RR4) |
Chest radiotherapy for Hodgkin’s lymphoma—rate of CBC unknown |
Young age at diagnosis—<30 years 0.5–1.3 % annual CBC rate Level II evidence (Nichols, Lacey JCO 2011) [2] |
ER status—ER positive (reference point RR 1) —ER negative (RR 1.3) Level II evidence [26] |
Anti-endocrine treatment (risk reduction), tamoxifen 50 % Aromatase inhibitor 70 % |
DCIS—0.6 % annual CBC risk of DCIS and/or invasive carcinoma (RR 1.0) Level I evidence [21] |
Lobular histology combined with family history (RR2.0) |
Oophorectomy under 40 years (risk reduction) (RR0.5) |
Early menopause <45 year (risk-reduction)—published as abstract [29] |